Table 2.
Sliding windows demonstrating a significant association among both discovery (p < 1.1 × 10−9) and replication (p < 0.01) stages for the T5 burden test
| Metabolite | Discovery (AA) | Replication (EA) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Window (gene) | P | Beta | cMAC | VarExp | Window (gene) | P | Beta | cMAC | VarExp | |
| N-acetyl-1-methylhistidine | Chr2: 73744005–73748004 (NAT8) | 1.6 × 10−15 | 0.12 | 933 | 1.0% | Chr2: 73744005–73748004 (NAT8) | 0.0004 | 0.17 | 156 | 0.5% |
| N-acetyl-1-methylhistidine | Chr2: 73614005–73618004 (NAT8) | 6.2 × 10−11 | −0.11 | 728 | 0.7% | Chr2: 73614005–73618004 (NAT8) | 0.005 | −0.07 | 336 | 0.2% |
| Acisoga | Chr6: 132952009–132956008 (VNN1) | 9.4 × 10−10 | 0.06 | 1504 | 0.4% | Chr6: 132952009–132956008 (VNN1) | 0.009 | −0.04 | 764 | 0.1% |
cMAC cumulative minor allele count, VarExp variance explained by the loci